77 completed, 31 terminated, 19 active not recruiting, 18 recruiting. 172 Phase 1, 72 Phase 2.
Follow Glioblastoma Multiforme: new trials by email Literature Review of Glioblastoma Multiforme trials Research Report on Glioblastoma Multiforme
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NG101m Adjuvant Therapy in Glioblastoma Patients Intensity-modulated radiation therapy, Temozolomide, NG101m - Glioblastoma Multiforme | Phase 1 / Phase 2 | Not yet recruiting | NeuGATE Theranostics | 52 | 2027-01-01 | 2025-10-21 |
| Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma LMP744, Conventional Surgery or Biopsy - Recurrent Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Phase 1 / Phase 2 | Recruiting | National Institute of Neurological Disorders and Stroke (NINDS) | 40 | 2026-07-15 | 2026-10-16 |
| Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status) S-Gboxin - Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant | Phase 1 | Suspended | Petrov, Andrey | 10 | 2026-05-20 | 2026-06-03 |
| Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy - Melanoma, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Recruiting | University of Arizona | 30 | 2025-09-08 | 2026-10-06 |
| Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age SIACI of cetuximab and bevacizumab - Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 1 / Phase 2 | Recruiting | University of Miami | 20 | 2025-06-19 | 2025-12-08 |
| Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM) NaviFUS System, Lumason, Bevacizumab - Glioblastoma Multiforme, Glioblastoma | Phase 1 / Phase 2 | Suspended | NaviFUS Corporation | 10 | 2024-10-22 | 2026-09-09 |
| Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma TS-2021 - Glioblastoma Multiforme, Glioma, Malignant | Phase 1 | Unknown | Beijing Neurosurgical Institute | 30 | 2024-08-29 | 2024-10-31 |
| Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma hypofractionated stereotactic radiotherapy, Stereotactic biopsy, resection - Glioblastoma, Glioblastoma Multiforme | Phase 1 | Recruiting | Hospital San Carlos, Madrid | 12 | 2024-03-21 | 2024-05-16 |
| T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma Allogeneic cytomegalovirus-specific T cells, Pembrolizumab - Glioblastoma Multiforme, Astrocytoma, Grade IV | Phase 1 / Phase 2 | Active not recruiting | Queensland Institute of Medical Research | 58 | 2024-02-08 | 2026-06-26 |
| Sonodynamic Therapy in Patients With Recurrent GBM 5-ALA and Low-Intensity Focused Ultrasound (SDT) - Recurrent Glioblastoma, Glioblastoma Multiforme | Phase 1 | Recruiting | Shayan Moosa, MD | 11 | 2024-01-31 | 2026-04-28 |
| Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab APG-157 - Glioma, Glioblastoma Multiforme | Phase 1 / Phase 2 | Active not recruiting | Aveta Biomics, Inc. | 30 | 2023-12-13 | 2026-10-05 |
| A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. 68Ga-FF58, 177Lu-FF58 - Pancreatic Ductal Adenocarcinoma, Gastroesophageal Adenocarcinoma | Phase 1 | Terminated | Novartis Pharmaceuticals | 24 | 2023-10-06 | 2025-12-24 |
| Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells pH Measurement of in vivo tissue - Glioblastoma Multiforme, Glycolytic Index | Phase 1 / Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 50 | 2023-09-06 | 2026-10-08 |
| IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells - Glioblastoma Multiforme, Glioblastoma | Phase 1 | Active not recruiting | University of Florida | 39 | 2023-07-25 | 2026-09-23 |
| Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma Eflornithine (Dose Level 1), Eflornithine (Dose Level 2), Eflornithine (Dose Level -1) - Glioblastoma, IDH-wildtype, Glioblastoma | Phase 1 | Recruiting | Orbus Therapeutics, Inc. | 66 | 2023-07-24 | 2025-06-25 |
| Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma Low-dose OKN-007, BID, Low-dose OKN-007, TID, Mid-dose OKN-007, TID - High-grade Glioma, Oligodendroglioma | Phase 1 | Active not recruiting | Oblato, Inc. | 16 | 2023-04-17 | 2024-11-29 |
| 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2) 131I-IPA - Neoplastic Disease, Glioblastoma | Phase 1 | Active not recruiting | Telix Pharmaceuticals (Innovations) Pty Limited | 12 | 2023-04-01 | 2026-08-13 |
| A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma C5252 - Solid Tumor, Glioblastoma | Phase 1 | Unknown | ImmVira Pharma Co. Ltd | 51 | 2023-03-15 | 2022-10-12 |
| A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma Ferumoxytol injection, Pharmacological ascorbate, External beam radiation therapy - Glioblastoma, Glioblastoma Multiforme | Phase 1 | Active not recruiting | Bryan Allen | 16 | 2023-02-28 | 2026-07-20 |
| Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS) - Malignant Glioma of Brain, Astrocytoma | Phase 1 | Recruiting | Henry Ford Health System | 18 | 2022-11-29 | 2025-12-16 |
Showing 20 of 172. Sign in to see all of them.
Glioblastoma (172) · Glioma (52) · Brain Neoplasms (49) · Astrocytoma (45) · Neoplasms (21) · Oligodendroglioma (18) · Gliosarcoma (15) · Recurrence (12) · Carcinoma, Non-Small-Cell Lung (7) · Ependymoma (6) · Carcinoma, Renal Cell (5) · Central Nervous System Neoplasms (5) · Diffuse Intrinsic Pontine Glioma (5) · Melanoma (5) · Breast Neoplasms (4)
Neoplasms, Germ Cell and Embryonal (171) · Neoplasms, Glandular and Epithelial (171) · Neoplasms, Neuroepithelial (171) · Neuroectodermal Tumors (171) · Neoplasms by Histologic Type (170) · Neoplasms, Nerve Tissue (169) · Neoplasms (151) · Astrocytoma (127) · Glioma (120) · Neoplasms by Site (65) · Nervous System Diseases (53) · Nervous System Neoplasms (52) · Brain Diseases (51) · Central Nervous System Diseases (50) · Central Nervous System Neoplasms (49)
Temozolomide (42) · Bevacizumab (24) · Radiotherapy (15) · Surgical Procedures, Operative (8) · Carboplatin (5) · Cyclophosphamide (5) · IL13-PE38 (5) · Radiosurgery (5) · Flucytosine (4) · Radiation (4) · pembrolizumab (4) · Carmustine (3) · Cetuximab (3) · Imiquimod (3) · Irinotecan (3)
Northwell Health (7) · INSYS Therapeutics Inc (5) · M.D. Anderson Cancer Center (5) · AbbVie (3) · Celgene (3) · National Cancer Institute (NCI) (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · Tocagen Inc. (3) · Ann & Robert H Lurie Children's Hospital of Chicago (2) · Beijing Neurosurgical Institute (2) · Beijing Sanbo Brain Hospital (2) · Boston Scientific Corporation (2) · Celularity Incorporated (2) · Dana-Farber Cancer Institute (2) · Gilead Sciences (2)
United States (131) · Australia (6) · Germany (6) · Spain (6) · United Kingdom (6) · China (5) · France (5) · Canada (4) · Israel (4) · Netherlands (4) · Switzerland (3) · Austria (2) · Denmark (2) · Italy (2) · Finland (1)
John Boockvar, MD (5) · Asha Das, MD (3) · Andrew Sloan, MD (2) · David Reardon, MD (2) · E. Antonio Chiocca, MD, PhD (2) · John M. Buatti, MD (2) · Lawrence Kleinberg, MD (2) · Maciej S Lesniak, MD (2) · Sean Grimm, MD (2) · Abi Vainstein-Haras, MD (1) · Adam M Sonabend, MD (1)
PMID 16520474, PMID 19534336, PMID 19760366, PMID 21844505, PMID 22284691, PMID 22483738, PMID 22931705, PMID 23560574, PMID 23844725, PMID 23891088, PMID 24026531, PMID 24947313, PMID 25915780, PMID 25944802, PMID 26106073, PMID 26541586, PMID 28291390, PMID 28366679, PMID 28548889, PMID 28558150, PMID 28679770, PMID 28720549, PMID 29533458, PMID 29762717, PMID 29982805, PMID 30786188, PMID 30796037, PMID 31189049, PMID 31413142, PMID 31707687, PMID 31853198, PMID 32373649, PMID 32946924, PMID 33284237, PMID 33292598, PMID 33604574, PMID 33741442, PMID 33888901, PMID 33939067, PMID 34214495, PMID 34359048, PMID 34609773, PMID 34862245, PMID 34911992, PMID 35022322, PMID 35552677, PMID 35728046, PMID 36845633, PMID 37142373, PMID 37609003
UM1CA081457 (3), 2014 (1), 2018 (1), 2023 (1), P30CA086862 (1), P50CA097257 (1), P50CA221747 (1), R01CA125244 (1), R21CA256421 (1), R21CA270742 (1), R42CA153845 (1), U01CA062502 (1), U01CA140206 (1)